concise.news
SearchSign inGet the Brief
Today
‹ Today
9 ·Health9 ·Health

FDA requires GLP-1 drugs to warn about potential vision loss risk.

NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.

SourcesSTAT15:56 UTCMarketWatch17:52 UTCQuartz18:50 UTCThe Independent20:20 UTCAP News20:27 UTCThe Washington Post20:50 UTCNew York Post20:51 UTCGizmodo21:46 UTCCBS News00:09 UTCFollowSaveHighlight
STAT, MarketWatch, Quartz, The Independent, AP News and 4 more

By concise.news.

Key points

From 5 outlets
  • FDA warns GLP-1 drugs carry risk of non-arteritic anterior ischemic optic neuropathy. SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STATSourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
  • NAION is an eye stroke caused by insufficient blood flow to the optic nerve. SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
  • Symptoms include sudden vision loss and potential blindness; no proven treatment exists. SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
  • Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have high real-world usage. SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
  • Regulators require manufacturers to inform patients and doctors about the risk. SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
  • FDA adds a new warning to GLP-1 weight loss and diabetes drugs. SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
  • Risk observed in about 6 of 100,000 GLP-1 users for at least one year. SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
  • Placebo or other glucose-lowering meds show less than 4 per 100,000. SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
  • NAION can cause permanent vision loss with limited or no cure. SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
  • Study suggests fourfold increased NAION risk among diabetes patients using semaglutide. SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
  • Healthcare providers told to monitor symptoms and refer to ophthalmology if NAION suspected. SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
  • Warning appears in the Warnings and Precautions section of drug labeling. SourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at Quartz

Quotes

  • “If a patient has had a NAION event, they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it”
    FDASourceGizmodo21:46 UTCSourceGizmodo21:46 UTC

Why it matters. These widely used drugs carry a low absolute risk of permanent blindness.

What to watch. Reports of sudden vision changes.

How it spread

First reported by STAT at 15:56 on Monday 9 November. 7 more outlets had it within 6 h.

05109 Nov06:0012:0018:0010 Nov06:009 outlets
  1. STAT, 15:56 on Monday 9 November
  2. MarketWatch, 17:52 on Monday 9 November
  3. Quartz, 18:50 on Monday 9 November
  4. The Independent, 20:20 on Monday 9 November
  5. AP News, 20:27 on Monday 9 November
  6. The Washington Post, 20:50 on Monday 9 November
  7. New York Post, 20:51 on Monday 9 November
  8. Gizmodo, 21:46 on Monday 9 November
  9. CBS News, 00:09 on Tuesday 10 November
Sourceconcise.newsEach outlet in Coverage, at its first report of this story in the 36 h before the Brief. Outlets that ran the same wire story each count.From each outlet’s feed

Coverage

Oldest first · UTC

“STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition”

“The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that’s sometimes referred to as an “eye stroke.””

Key points from STAT
  • FDA warns GLP-1 drugs carry risk of non-arteritic anterior ischemic optic neuropathy.
  • NAION is an eye stroke caused by insufficient blood flow to the optic nerve.
  • Symptoms include sudden vision loss and potential blindness; no proven treatment exists.
  • Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have high real-world usage.
  • Regulators require manufacturers to inform patients and doctors about the risk.
SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT

“FDA is requiring weight loss drug makers to add a vision loss warning”

“The warning covers all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a rare eye condition called NAION”

Key points from Quartz
  • FDA mandates warning about NAION, an uncommon eye disorder risking permanent vision loss.
  • Label changes apply to Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo.
  • Warning appears in the Warnings and Precautions section of drug labeling.
  • Meta-analysis found 6.4 NAION cases per 100,000 person-years on GLP-1 drugs.
  • FDA reviewed trial and postmarketing data; no clear mechanism identified.
SourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at Quartz

“FDA adds rare vision-loss warning to popular GLP-1 drugs”

“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic”

Key points from The Independent
  • FDA adds a new warning to GLP-1 weight loss and diabetes drugs.
  • Eye condition non-arteritic anterior ischemic optic neuropathy can cause vision loss.
  • Risk observed in about 6 of 100,000 GLP-1 users for at least one year.
  • Placebo or other glucose-lowering meds show less than 4 per 100,000.
  • Warnings apply to brands like Ozempic, Wegovy, Zepbound, and Mounjaro.
SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent

“GLP-1 drugs must have new warning label over incurable blindness condition, says FDA”

Key points from New York Post
  • FDA warns GLP-1 drugs may increase risk of nonarteritic anterior ischemic optic neuropathy.
  • Agency orders safety label updates for Ozempic, Wegovy, Zepbound, Mounjaro and others.
  • NAION can cause permanent vision loss with limited or no cure.
  • Study suggests fourfold increased NAION risk among diabetes patients using semaglutide.
  • Healthcare providers told to monitor symptoms and refer to ophthalmology if NAION suspected.
SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post

“FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s”

“Health regulators have found a consistent link between GLP-1 use and the eye condition NAION.”

Key points from Gizmodo
  • FDA orders warning on labeling for semaglutide and other GLP-1s about NAION.
  • NAION is a rare, potentially permanent vision loss from reduced optic nerve blood flow.
  • Higher risk seen in people over 50 with hypertension; absolute risk still low.
  • European agencies independently flagged GLP-1 NAION as very rare, up to 1 in 10,000.
  • Patients should monitor vision changes and consult doctors promptly if affected.
SourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at Gizmodo

“FDA warns of rare vision-loss side effect from GLP-1 drugs”

“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.”

Key points from CBS News
  • FDA requires a warning for all GLP-1 drugs, including Ozempic and Wegovy.
  • The eye condition NAION can cause partial or permanent vision loss.
  • FDA analysis: roughly 6 in 100,000 GLP-1 users for at least one year affected.
  • Placements of the warning followed a 2024 paper linking semaglutide to NAION.
  • Experts urge monitoring symptoms and consulting a healthcare professional promptly.
SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News

How it spread

First reported by STAT at 15:56 on Monday 9 November. 7 more outlets had it within 6 h.

05109 Nov12:0010 Nov9 outlets
  1. STAT, 15:56 on Monday 9 November
  2. MarketWatch, 17:52 on Monday 9 November
  3. Quartz, 18:50 on Monday 9 November
  4. The Independent, 20:20 on Monday 9 November
  5. AP News, 20:27 on Monday 9 November
  6. The Washington Post, 20:50 on Monday 9 November
  7. New York Post, 20:51 on Monday 9 November
  8. Gizmodo, 21:46 on Monday 9 November
  9. CBS News, 00:09 on Tuesday 10 November
Sourceconcise.newsEach outlet in Coverage, at its first report of this story in the 36 h before the Brief. Outlets that ran the same wire story each count.From each outlet’s feed

Coverage

Oldest first · UTC
SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT“STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition”

“The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that’s sometimes referred to as an “eye stroke.””

Key points from STAT
  • FDA warns GLP-1 drugs carry risk of non-arteritic anterior ischemic optic neuropathy.
  • NAION is an eye stroke caused by insufficient blood flow to the optic nerve.
  • Symptoms include sudden vision loss and potential blindness; no proven treatment exists.
  • Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have high real-world usage.
  • Regulators require manufacturers to inform patients and doctors about the risk.
SourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at Quartz“FDA is requiring weight loss drug makers to add a vision loss warning”

“The warning covers all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a rare eye condition called NAION”

Key points from Quartz
  • FDA mandates warning about NAION, an uncommon eye disorder risking permanent vision loss.
  • Label changes apply to Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo.
  • Warning appears in the Warnings and Precautions section of drug labeling.
  • Meta-analysis found 6.4 NAION cases per 100,000 person-years on GLP-1 drugs.
  • FDA reviewed trial and postmarketing data; no clear mechanism identified.
SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent“FDA adds rare vision-loss warning to popular GLP-1 drugs”

“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic”

Key points from The Independent
  • FDA adds a new warning to GLP-1 weight loss and diabetes drugs.
  • Eye condition non-arteritic anterior ischemic optic neuropathy can cause vision loss.
  • Risk observed in about 6 of 100,000 GLP-1 users for at least one year.
  • Placebo or other glucose-lowering meds show less than 4 per 100,000.
  • Warnings apply to brands like Ozempic, Wegovy, Zepbound, and Mounjaro.
SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post“GLP-1 drugs must have new warning label over incurable blindness condition, says FDA”
Key points from New York Post
  • FDA warns GLP-1 drugs may increase risk of nonarteritic anterior ischemic optic neuropathy.
  • Agency orders safety label updates for Ozempic, Wegovy, Zepbound, Mounjaro and others.
  • NAION can cause permanent vision loss with limited or no cure.
  • Study suggests fourfold increased NAION risk among diabetes patients using semaglutide.
  • Healthcare providers told to monitor symptoms and refer to ophthalmology if NAION suspected.
SourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at Gizmodo“FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s”

“Health regulators have found a consistent link between GLP-1 use and the eye condition NAION.”

Key points from Gizmodo
  • FDA orders warning on labeling for semaglutide and other GLP-1s about NAION.
  • NAION is a rare, potentially permanent vision loss from reduced optic nerve blood flow.
  • Higher risk seen in people over 50 with hypertension; absolute risk still low.
  • European agencies independently flagged GLP-1 NAION as very rare, up to 1 in 10,000.
  • Patients should monitor vision changes and consult doctors promptly if affected.
SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News“FDA warns of rare vision-loss side effect from GLP-1 drugs”

“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.”

Key points from CBS News
  • FDA requires a warning for all GLP-1 drugs, including Ozempic and Wegovy.
  • The eye condition NAION can cause partial or permanent vision loss.
  • FDA analysis: roughly 6 in 100,000 GLP-1 users for at least one year affected.
  • Placements of the warning followed a 2024 paper linking semaglutide to NAION.
  • Experts urge monitoring symptoms and consulting a healthcare professional promptly.

AI wrote this story from the reports above. No person checked it before it was published. How concise.news works

How it travelled

The United States’ press was first, at 15:56 on Monday 9 November.

and 15 more countries
  • A report of the story
  • A related report

Not drawn: CNN, El Comercio and 2 more. They ran only copies.

  • In the story
    1. Elsewhere
      1. United States: 16 outlets, the first at 15:56 on Monday 9 November
        • STAT, at 15:56 on Monday 9 November
        • medpagetoday.com, at 16:29 on Monday 9 November
        • MarketWatch, at 17:52 on Monday 9 November
        • NBC News, at 18:14 on Monday 9 November
        • qz.com, at 18:50 on Monday 9 November; a related report at 21:54 on Monday 9 November
        • AP News, at 20:27 on Monday 9 November
        • The Washington Post, at 20:50 on Monday 9 November
        • New York Post, at 20:51 on Monday 9 November
        • The Hill, at 21:33 on Monday 9 November
        • Gizmodo, at 21:46 on Monday 9 November
        • CBS News, at 00:09 on Tuesday 10 November
        • CNBC, at 07:52 on Tuesday 10 November
        • The Washington Times, at 13:04 on Tuesday 10 November, a related report
        • Ars Technica, at 14:43 on Tuesday 10 November
        • The Daily Beast, at 16:03 on Tuesday 10 November, a related report
        • La Opinion, at 17:01 on Tuesday 10 November
      2. France: 1 outlet, the first at 17:19 on Monday 9 November
        • Euronews, at 17:19 on Monday 9 November
      3. United Kingdom: 6 outlets, the first at 17:20 on Monday 9 November
        • Reuters, at 15:59 on Monday 9 November, a related report
        • Financial Times, at 17:20 on Monday 9 November
        • The Independent, at 17:21 on Monday 9 November; a related report at 14:35 on Tuesday 10 November
        • Sky News, at 00:24 on Tuesday 10 November
        • BBC, at 18:43 on Tuesday 10 November
        • The Guardian, at 20:18 on Tuesday 10 November
      4. Austria: 1 outlet, the first at 17:44 on Monday 9 November
        • Der Standard, at 17:44 on Monday 9 November
      5. Türkiye: 1 outlet, the first at 19:43 on Monday 9 November
        • Anadolu Agency, at 19:43 on Monday 9 November
      6. XK: 1 outlet, the first at 21:50 on Monday 9 November
        • Koha Ditore, at 21:50 on Monday 9 November
      7. South Korea: 5 outlets, the first at 23:08 on Monday 9 November
        • Dong-A Ilbo, at 23:08 on Monday 9 November
        • SBS News, at 23:12 on Monday 9 November
        • Chosun Ilbo, at 00:19 on Tuesday 10 November
        • Maeil Business, at 04:21 on Tuesday 10 November
        • The Korea Times, at 05:07 on Wednesday 11 November
      8. Taiwan: 2 outlets, the first at 02:39 on Tuesday 10 November
        • Central News Agency, at 02:39 on Tuesday 10 November
        • PTS News, at 12:26 on Wednesday 11 November, a related report
      9. Norway: 1 outlet, the first at 03:56 on Tuesday 10 November
        • VG, at 03:56 on Tuesday 10 November
      10. Hong Kong: 1 outlet, the first at 04:26 on Tuesday 10 November
        • Sing Tao Headline, at 04:26 on Tuesday 10 November
      11. Israel: 4 outlets, the first at 04:26 on Tuesday 10 November
        • Ynet, at 04:26 on Tuesday 10 November
        • Globes, at 07:00 on Tuesday 10 November, a related report
        • Arutz Sheva (Israel National News), at 09:10 on Tuesday 10 November
        • Srugim, at 19:29 on Tuesday 10 November, a related report
      12. Malaysia: 2 outlets, the first at 05:58 on Tuesday 10 November
        • Berita Harian, at 05:58 on Tuesday 10 November
        • Utusan Malaysia, at 01:30 on Wednesday 11 November
      13. United Arab Emirates: 2 outlets, the first at 07:57 on Tuesday 10 November
        • Sky News Arabia, at 07:57 on Tuesday 10 November
        • The National, at 16:59 on Tuesday 10 November
      14. Iran: 2 outlets, the first at 08:55 on Tuesday 10 November
        • Shargh, at 08:55 on Tuesday 10 November
        • Ham-Mihan, at 11:14 on Tuesday 10 November
      15. Czechia: 1 outlet, the first at 10:10 on Tuesday 10 November
        • ČT24, at 10:10 on Tuesday 10 November, a related report
      16. India: 4 outlets, the first at 10:18 on Tuesday 10 November
        • Mint, at 10:18 on Tuesday 10 November
        • Mathrubhumi, at 12:52 on Tuesday 10 November
        • The Economic Times, at 18:46 on Tuesday 10 November
        • BusinessLine, at 07:01 on Wednesday 11 November
      17. Japan: 1 outlet, the first at 10:41 on Tuesday 10 November
        • FNN Prime Online (Fuji TV), at 10:41 on Tuesday 10 November
      18. Saudi Arabia: 2 outlets, the first at 11:10 on Tuesday 10 November
        • Ajel, at 22:05 on Monday 9 November, a related report
        • Sabq, at 11:10 on Tuesday 10 November; a related report at 08:37 on Tuesday 10 November
      19. Cyprus: 1 outlet, the first at 13:07 on Tuesday 10 November
        • Sigmalive, at 13:07 on Tuesday 10 November, a related report
      20. Brazil: 3 outlets, the first at 15:46 on Tuesday 10 November
        • Veja, at 15:15 on Tuesday 10 November, a related report
        • O Globo, at 15:46 on Tuesday 10 November
        • Metrópoles, at 18:42 on Tuesday 10 November
      21. Canada: 1 outlet, the first at 18:17 on Tuesday 10 November
        • Global News, at 18:17 on Tuesday 10 November
      22. Australia: 1 outlet, the first at 23:07 on Tuesday 10 November
        • The Conversation, at 23:07 on Tuesday 10 November
      23. Greece: 1 outlet, the first at 10:07 on Wednesday 11 November
        • ERTnews, at 10:07 on Wednesday 11 November
    Sourceconcise.newsEach outlet’s first report of this story, by its country.Reports from 24 h before the Brief to 48 h after.Found after the Brief picked its stories. They don’t change its ranking.From each outlet’s feedPress freedom: RSF World Press Freedom Index 2026Checked 16:54 on Wednesday 11 November

    Why it’s in the Brief

    Ranked 9th of 10.

    Starting score
    5.0
    Public-interest topic
    +1.0
    Public-interest terms in the text
    +1.25
    High-reliability sources
    +0.75
    Corroboration by independent outlets
    +0.8
    Score
    8.8

    The ranking is the same for everyone.

    Perspective mix. 2 center-left · 3 center · 1 center-right · 3 unrated.RatingsAllSides and Media Bias/Fact CheckLean and credibility are curated from their public ratings.Unknown outlets stay unrated, never guessed.

    Blindspot. 8 of 9 outlets are United States-based. Worth knowing before you make up your mind.

    Since then

    From the archive

    In the Brief of Wednesday 11 November

    Since then

    From the archive

    In the Brief of Wednesday 11 November